<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-418</article-id><article-id pub-id-type="pmid">19948069</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-418</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title>Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Dai</surname><given-names>Chen-Xin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>daichenxin@gmail.com</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Gao</surname><given-names>Qiang</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>qgao1981@gmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Qiu</surname><given-names>Shuang-Jian</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>qiu.shuangjian@zs-hospital.sh.cn</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Ju</surname><given-names>Min-Jie</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>juminjie@hotmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Cai</surname><given-names>Ming-Yan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>catcai@gmail.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Xu</surname><given-names>Yong-Feng</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>xuyongfengsh@gmail.com</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Zhou</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jianzhou99@yahoo.com</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Zhang</surname><given-names>Bo-Heng</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>bzhang@zshospital.com</email></contrib><contrib contrib-type="author" corresp="yes" id="A9"><name><surname>Fan</surname><given-names>Jia</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jiafan99@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Shanghai, PR China</aff><aff id="I2"><label>2</label>Institute of Biomedical Sciences, Fudan University, Shanghai, PR China</aff><aff id="I3"><label>3</label>Center for Evidence Based Medicine, Fudan University, Shanghai, PR China</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>1</day><month>12</month><year>2009</year></pub-date><volume>9</volume><fpage>418</fpage><lpage>418</lpage><history><date date-type="received"><day>24</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Dai et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Dai et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/9/418"/><abstract><sec><title>Background</title><p>Despite well-studied tumor hypoxia in laboratory, little is known about the association with other pathophysiological events in the clinical view. We investigated the prognostic value of hypoxia-inducible factor-1 alpha (HIF-1alpha) in hepatocellular carcinoma (HCC), and its correlations with inflammation, angiogenesis and MYC oncogene.</p></sec><sec><title>Methods</title><p>In a random series of 110 HCC patients, the mRNA of HIF-1alpha, inflammation related factors (COX-2, MMP7 and MMP9), angiogenesis related factors (VEGF and PDGFRA) and MYC in tumor tissue were detected by real-time RT-PCR and HIF-1alpha protein was assessed by immunohistochemistry. The correlations between HIF-1alpha mRNA and the factors mentioned previously, the relationship between HIF-1alpha and clinicopathologic features, and the prognostic value were analyzed.</p></sec><sec><title>Results</title><p>The expression of both HIF-1alpha mRNA and protein in HCC were independent prognostic factors for overall survival (OS) (<italic>P </italic>= 0.012 and <italic>P </italic>= 0.021, respectively) and disease-free survival (DFS) (<italic>P </italic>= 0.004 and <italic>P </italic>= 0.007, respectively) as well. Besides, the high expression of HIF-1alpha mRNA and protein proposed an advanced BCLC stage and more incidence of vascular invasion. The mRNA of HIF-1alpha had significantly positive correlations to that of COX-2, PDGFRA, MMP7, MMP9, MYC, except VEGF. In addition to HIF-1alpha, COX-2 and PDGFRA were also independent prognosticators for OS (<italic>P </italic>= 0.004 and <italic>P </italic>= 0.010, respectively) and DFS (<italic>P </italic>= 0.010 and <italic>P </italic>= 0.038, respectively).</p></sec><sec><title>Conclusion</title><p>HIF-1alpha in HCC plays an important role in predicting patient outcome. It may influence HCC biological behaviors and affect the tumor inflammation, angiogenesis and act in concert with the oncogene MYC. Attaching importance to HIF-1alpha in HCC may improve the prognostic and therapeutic technique.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p><bold>HEPATOCELLULAR </bold>carcinoma (HCC) is the sixth most common cancer and the third most common cause of death from cancer worldwide, with increasing incidence in western countries [<xref ref-type="bibr" rid="B1">1</xref>]. Surgical resection provides an opportunity for cure, but the outcome remains dismal due to frequent tumor recurrence. Recently, better appreciations of the role that tumor microenvironment plays in tumor progression have bring a paradigm shift in developing strategies for cancer management. As a consequence, renewed emphasis has been placed on key features of the tumor microenvironment, in particular hypoxia, leading us to explore hypoxia related parameters for more accurate classification of this fetal disease.</p><p>As is well-recognized, hypoxia is a common mechanism in HCC as the solid tumor owing to aberrant visualization [<xref ref-type="bibr" rid="B2">2</xref>]. Accumulating data have shown that hypoxia can stimulate proliferation[<xref ref-type="bibr" rid="B3">3</xref>], induce angiogenesis [<xref ref-type="bibr" rid="B4">4</xref>], accelerate invasion [<xref ref-type="bibr" rid="B5">5</xref>] and is responsible for treatment resistance in HCC [<xref ref-type="bibr" rid="B6">6</xref>]. The adaptation of HCC cells to tissue hypoxia is of central importance for tumor progression, where inducing the ubiquitous transcription factor of hypoxia-inducible factor-1&#x003b1; (HIF-1&#x003b1;) expression appears to be a critical step [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>HIF-1&#x003b1; is a master regulator of essential adaptive responses to hypoxia, whose expression and transcriptional activity increasing exponentially with decreases in levels of cellular oxygen. In tumors, HIF-1&#x003b1; regulates proliferation, apoptosis, metastatic spread, and glucose metabolism by acting as a transcription factor for crucial proteins [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Previous studies have been focusing on the clinical significance as well as experimental models of HIF-1&#x003b1; in many types of cancer, which have led to somewhat controversial results [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. On the basis of its unquestioned role as a central regulator of tumor pathophysiology, elucidating HIF-1&#x003b1;'s prognostic value in HCC is of great clinical importance, which may lead to better patient stratification and provide rational for hypoxia targeted therapies.</p><p>Importantly, the presence of hypoxia is always associated with and accompanied by inflammation and angiogenesis [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Specifically, HIF-1&#x003b1; and the oncogene MYC, which is also a transcription factor, act in concert to "fine tune" cancer cells' adaptive responses to hypoxic environments [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>In the present study, we measured mRNA expression of HIF-1&#x003b1; in tumor tissue from 110 randomly selected HCC patients. We found that HIF-1&#x003b1; expression was associated with aggressive phenotypes of HCC and could be an independent prognostic factor for HCC patients after curative hepatectomy. Meanwhile, we presented the real-time reverse-transcriptase polymerise-chain-reaction (RT-PCR) study in the same cohort of patients on a battery of core genes which play important roles in inflammation (COX-2, MMP7, MMP9) [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>] and angiogenesis (VEGF, PDGFRA) [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>], as well as MYC which was confirmed as a key hypoxia regulator [<xref ref-type="bibr" rid="B19">19</xref>], to find the correlation of HIF-1&#x003b1; with these factors that can also affect and reflect tumor behaviors. These factors were selected for at least two of the three aspects: being crucial in inflammation or angiogenesis; being active in tumor metastasis or invasion; being mechanistically related to hypoxia. At last, using in situ immunostaining of HIF-1&#x003b1; protein, we got a further confirmation of the clinical significance of this crucial factor.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and Specimens</title><p>Under the following the inclusion and exclusion criteria: (a) distinctive pathologic diagnosis of HCC, (b) without anticancer treatment and distant metastases before surgery, (c) underwent primary and curative resection for HCC between 2002 and 2005, defined as macroscopically complete removal of the tumor, as described previously [<xref ref-type="bibr" rid="B20">20</xref>], and (d) with complete clinicopathologic and follow-up data, about 2000 patients underwent hepatectomy at Zhongshan Hospital, Fudan University between 2002 and 2005 were identified. Following approval by the Institutional Review Board, a total of 110 patients in this time, with available frozen tumor specimens from our prospectively established tissue bank, were chosen randomly to be entered in this retrospective study. The mean age of patients was 52.4 years (range: 28-75) and all the patients were classified with Barcelona Clinic Liver Cancer staging system (BCLC stage) [<xref ref-type="bibr" rid="B21">21</xref>]. Informed consent was obtained from all patients.</p><p>A diagnosis of recurrence was confirmed by an elevated AFP level and typical imaging appearance in computed tomography and/or magnetic resonance imaging scan [<xref ref-type="bibr" rid="B20">20</xref>]. Overall survival (OS) was defined as the interval from surgery and death. Disease-free survival time (DFS) was defined as the interval from surgery to recurrence. The data was censored on last follow-up for living patients or for the patients in whom tumor recurrence was not diagnosed. The median follow-up time was 24.0 months (range: 1.5-68.0 mon; SE: 1.49).</p></sec><sec><title>Real-time RT-PCR</title><p>Total RNA was isolated from each specimen with Trizol reagent (Invitrogen, Carlsbad, CA) and then reverse transcribed with the oligo dT primers and SuperScript RT (Invitrogen). The PCR primers used were showed in Table <xref ref-type="table" rid="T1">1</xref>. Quantitative real-time RT-PCR was performed by using a 384-well ABI 7900 HT (Applied Biosystems, Foster City, CA). In particular, for a single gene, PCR amplifications of all the 110 specimens were simultaneously performed on the same 384-well plate in duplicate to avoid potential variations. Duplicate RT-PCR samples in each assay were collapsed by averaging.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Forward and reverse primers for the genes analyzed</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">Forward primer</th><th align="left">Reverse primer</th></tr></thead><tbody><tr><td align="left">HIF-1&#x003b1;</td><td align="left">5'CTGCTGTCTTACTGGTCCTT3'</td><td align="left">5'GTCGCTTCTCCA ATTCTTAC3'</td></tr><tr><td align="left">COX-2</td><td align="left">5'CCATTCAGTTCCCACCATCT3'</td><td align="left">5'TCACTGCTGTTGGGTCTCTG3'</td></tr><tr><td align="left">MMP7</td><td align="left">5'AGATGTGGAGTGCCAGATGT3'</td><td align="left">5'TAGACTGCTACCATCCGTCC3'</td></tr><tr><td align="left">MMP9</td><td align="left">5'GGCGCTCATGTACCCTATGT3'</td><td align="left">5'CCTGTGTACACCCACACCTG3'</td></tr><tr><td align="left">VEGF</td><td align="left">5'ATGAACTTTCTGCTCTCTGG3'</td><td align="left">5'TCATCTCTCCTATGTGCTGGC3'</td></tr><tr><td align="left">PDGFRA</td><td align="left">5'GGGGAAACGATTGTGGTCACC3'</td><td align="left">5'CCCGCACCTCTACAACAAAAT3'</td></tr><tr><td align="left">MYC</td><td align="left">5'AAAGGCCCCCAAGGTAGTTA3'</td><td align="left">5'TTTCCGCAACAAGTCCTCTT3'</td></tr><tr><td align="left">HPRT</td><td align="left">5'CCTGGCGTCGTGATTAGTG3'</td><td align="left">5'CAGAGGGCTACAATGTGATGG3'</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left">TBP</td><td align="left">5'ACCACTCCACTGTATCCCTCC3'</td><td align="left">5'CTGTTCTTCACTCTTGGCTCCT3'</td></tr></tbody></table></table-wrap><p>Cycling parameters were as follows: 2 min at 50&#x000b0;C and 10 min at 95&#x000b0;C followed by 40 cycles of 30 sec at 95&#x000b0;C and 2 min at 60&#x000b0;C. The relative changes in gene expression were calculated by the &#x00394;&#x00394;Ct method using the SDS 2.1 software according to the manufacturer's instructions (Applied-Biosystems). The expression of each gene was related to its expression in the reference RNA pool from the 10 normal liver tissues used as a calibrator. To control for variability in cDNA quantity, integrity, and individual primer efficiency, data were normalized against two housekeeping genes (TBP and HPRT) as we previously described [<xref ref-type="bibr" rid="B22">22</xref>]. (See Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Figure S1 for relative mRNA expression of HIF-1&#x003b1;, COX-2, MMP7, MMP9, VEGF, PDGFRA and MYC with the cut-off value determined by the X-tile software).</p></sec><sec><title>Tissue microarray and Immunohistochemistry</title><p>Tissue microarrays (TMA) were constructed as described previously [<xref ref-type="bibr" rid="B23">23</xref>]. Triplicates of 1-mm-diameter cylinders from representative areas of tumor center, away from necrotic, hemorrhagic and major fibrotic areas, were included in each case, along with different controls (spleen, lymph node, artery and glioma), to ensure reproducibility and homogenous staining of the slides. Serial sections (4 &#x003bc;m thick) were placed on slides coated with 3-aminopropyltriethoxysilane.</p><p>Immunohistochemical staining by the streptavidin-biotin-peroxidase complex method was performed as previously described. Rabbit polyclonal antibody to HIF-1&#x003b1; (ab65979; Abcam, Cambridge, UK) was used at a dilution of 1:50. Briefly, sections were dewaxed, hydrated, and washed. After neutralization of endogenous peroxidase and microwave antigen retrieval, slides were preincubated with blocking serum and then incubated overnight with the primary Ab. Then, the sections were serially rinsed, incubated with second antibodies, and treated with horseradish peroxidase-conjugated streptavidin. Reaction products were visualized with 3, 3'-diaminobenzidine tetrahydrochloride and counterstained with hematoxylin. For the negative control, the primary antibodies were replaced with phosphate buffered saline.</p><p>The manual evaluation of HIF-1&#x003b1; expression involved location and degree of reactivity. Location of expression included not only the cell type but also that of the subcellular localization (i.e., nucleus, cytoplasm). Degree of expression was determined by assessing semiquantitatively percentage of positive nuclear staining cells in random four fields of each core as well as evaluating for cytoplasmic staining intensity in the entire disk. The final result was classified as follows: I, no staining; II, nuclear staining in less than 10% of cells and/or with weak cytoplasmic staining; III, nuclear staining in 10%-50% of cells and/or with moderate cytoplasmic staining; IV, nuclear staining in more than 50% of cells and/or with strong cytoplasmic staining [<xref ref-type="bibr" rid="B24">24</xref>] In statistical analysis, the grades I and II were considered to be low expression of HIF-1&#x003b1; protein, with III and IV as high expression [<xref ref-type="bibr" rid="B25">25</xref>]. (See Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>: Table S1 for degree of HIF-1&#x003b1; immunohistochemical staining)</p><p>Two independent investigators blind to the clinicopathologic data assessed the immunohistochemistry. When independent scoring of a case differed, the case was rechecked, and the final score was determined by recounting HIF-1&#x003b1; positive nuclear staining cells using a multiheaded microscope with both reviewers simultaneously viewing the slides.</p></sec><sec><title>Statistical analysis</title><p>The statistical analysis was done with SPSS 15.0 program. To assess the relationship between experimental results and clinicopathologic characteristics, Fisher's exact test and Spearman's &#x003c1; coefficients test were carried out as appropriate. To find out the correlations between HIF-1&#x003b1; and other evaluated factors, Pearson Correlation test was used.</p><p>Patient survival distribution was calculated using the Kaplan-Meier method and compared with the log-rank test. Cut-point value of experiment results was determined by the X-tile software [<xref ref-type="bibr" rid="B26">26</xref>]. Univariate and multivariate analyses were based on the Cox proportional hazards regression model. All variables that were found to be statistical significant in univariate analysis were included in multivariate analysis. <italic>P </italic>&#x0003c; 0.05 (two-sided) was judged statistically significant.</p></sec></sec><sec><title>Results</title><sec><title>Correlation of HIF-1&#x003b1; mRNA to clinicopathologic features</title><p>According to the optimal cut-point value of HIF-1&#x003b1; determined by the X-tile software, the expression of HIF-1&#x003b1; mRNA was defined as high expression in 42 specimens (38.2%) and low expression in 68 specimens (61.8%). The HIF-1&#x003b1; mRNA expression level has no correlation to gender, tumor size, encapsulation, number, hepatitis history, liver cirrhosis and preoperative AFP level, while older patients seems to have tumor with higher HIF-1&#x003b1; expression (<italic>P </italic>= 0.049) (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Correlations of HIF-1&#x003b1; mRNA and protein with clinicopathological characters</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left" colspan="3">HIF-1&#x003b1; mRNA</th><th align="left" colspan="3">HIF-1&#x003b1; protein</th></tr><tr><th/><th colspan="6"><hr/></th></tr><tr><th/><th align="left">low</th><th align="left">high</th><th align="left"><italic>P</italic></th><th align="left">low</th><th align="left">high</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Patients</td><td align="left">68</td><td align="left">42</td><td/><td align="left">71</td><td align="left">39</td><td/></tr><tr><td align="left">Age(years)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02264;52</td><td align="left">28</td><td align="left">26</td><td align="left">0.049</td><td align="left">32</td><td align="left">22</td><td align="left">0.320</td></tr><tr><td align="left">&#x02003;&#x0003e;52</td><td align="left">40</td><td align="left">16</td><td/><td align="left">39</td><td align="left">17</td><td/></tr><tr><td align="left">Sex</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Male</td><td align="left">57</td><td align="left">38</td><td align="left">0.40</td><td align="left">57</td><td align="left">38</td><td align="left">0.017</td></tr><tr><td align="left">&#x02003;Female</td><td align="left">11</td><td align="left">4</td><td/><td align="left">14</td><td align="left">1</td><td/></tr><tr><td align="left">Hepatitis history</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">61</td><td align="left">39</td><td align="left">0.739</td><td align="left">62</td><td align="left">38</td><td align="left">0.094</td></tr><tr><td align="left">&#x02003;No</td><td align="left">7</td><td align="left">3</td><td/><td align="left">9</td><td align="left">1</td><td/></tr><tr><td align="left">Preoperative AFP(ng/ml)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02264;20</td><td align="left">29</td><td align="left">16</td><td align="left">0.693</td><td align="left">33</td><td align="left">12</td><td align="left">0.156</td></tr><tr><td align="left">&#x02003;&#x0003e;20</td><td align="left">39</td><td align="left">26</td><td/><td align="left">38</td><td align="left">27</td><td/></tr><tr><td align="left">Liver cirrhosis</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">59</td><td align="left">34</td><td align="left">0.428</td><td align="left">56</td><td align="left">37</td><td align="left">0.029</td></tr><tr><td align="left">&#x02003;No</td><td align="left">9</td><td align="left">8</td><td/><td align="left">15</td><td align="left">2</td><td/></tr><tr><td align="left">ALT(U/L)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02264;40</td><td align="left">36</td><td align="left">22</td><td align="left">1.000</td><td align="left">38</td><td align="left">20</td><td align="left">0.844</td></tr><tr><td align="left">&#x02003;&#x0003e;40</td><td align="left">32</td><td align="left">20</td><td/><td align="left">33</td><td align="left">19</td><td/></tr><tr><td align="left">&#x00393;-GT(U/L)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02264;54</td><td align="left">30</td><td align="left">14</td><td align="left">0.318</td><td align="left">31</td><td align="left">13</td><td align="left">0.316</td></tr><tr><td align="left">&#x02003;&#x0003e;54</td><td align="left">38</td><td align="left">28</td><td/><td align="left">40</td><td align="left">26</td><td/></tr><tr><td align="left">Tumor size (cm)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02264;5</td><td align="left">35</td><td align="left">21</td><td align="left">1.000</td><td align="left">33</td><td align="left">23</td><td align="left">0.236</td></tr><tr><td align="left">&#x02003;&#x0003e;5</td><td align="left">33</td><td align="left">21</td><td/><td align="left">38</td><td align="left">16</td><td/></tr><tr><td align="left">Tumor encapsulation</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">31</td><td align="left">18</td><td align="left">0.845</td><td align="left">32</td><td align="left">17</td><td align="left">1.000</td></tr><tr><td align="left">&#x02003;No</td><td align="left">37</td><td align="left">24</td><td/><td align="left">39</td><td align="left">22</td><td/></tr><tr><td align="left">Tumor number</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Single</td><td align="left">53</td><td align="left">32</td><td align="left">0.820</td><td align="left">56</td><td align="left">29</td><td align="left">0.638</td></tr><tr><td align="left">&#x02003;Multiple</td><td align="left">15</td><td align="left">10</td><td/><td align="left">15</td><td align="left">10</td><td/></tr><tr><td align="left">Vascular invasion</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">26</td><td align="left">25</td><td align="left">0.033</td><td align="left">27</td><td align="left">24</td><td align="left">0.027</td></tr><tr><td align="left">&#x02003;No</td><td align="left">42</td><td align="left">17</td><td/><td align="left">44</td><td align="left">15</td><td/></tr><tr><td align="left">BCLC stage</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;A</td><td align="left">30</td><td align="left">10</td><td align="left">0.041</td><td align="left">31</td><td align="left">9</td><td align="left">0.039</td></tr><tr><td align="left">&#x02003;B + C</td><td align="left">38</td><td align="left">32</td><td/><td align="left">40</td><td align="left">30</td><td/></tr><tr><td align="left">Tumor differentiation</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;I+II</td><td align="left">40</td><td align="left">18</td><td align="left">0.119</td><td align="left">36</td><td align="left">22</td><td align="left">0.690</td></tr><tr><td align="left">&#x02003;III+IV</td><td align="left">28</td><td align="left">24</td><td/><td align="left">35</td><td align="left">17</td><td/></tr><tr><td align="left">Prophylactic treatment</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">33</td><td align="left">22</td><td align="left">0.845</td><td align="left">31</td><td align="left">24</td><td align="left">0.110</td></tr><tr><td align="left">&#x02003;No</td><td align="left">35</td><td align="left">20</td><td/><td align="left">39</td><td align="left">16</td><td/></tr></tbody></table><table-wrap-foot><p>Detailed legends: Fisher's exact tests were used for all the analysis of correlations.</p></table-wrap-foot></table-wrap><p>The HIF-1&#x003b1; mRNA expression level showed significantly positive correlation with vascular invasion. In all the 110 patients, 59 cases without tumor vascular invasion have a high expression rate of 28.8%, as compared with the high expression rate of 49.0% (<italic>P </italic>= 0.033) in cases with vascular invasion. Also, the HIF-1&#x003b1; mRNA expression level was significantly correlated to BCLC stages. The HIF-1&#x003b1; mRNA expression in patients at stage A was lower than those at stages B and C (<italic>P </italic>= 0.041) (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>Correlation of HIF-1&#x003b1; to COX-2, MMP7, MMP9, VEGF, PDGFRA and MYC</title><p>Significant positive correlations were observed between HIF-1&#x003b1; mRNA and the putative markers of inflammation, angiogenesis and MYC: COX-2 (<italic>P </italic>&#x0003c; 0.001, <italic>r </italic>= 0.708), MMP7 (<italic>P </italic>&#x0003c; 0.001, <italic>r </italic>= 0.593), MMP9 (<italic>P </italic>&#x0003c; 0.001, <italic>r </italic>= 0.384), PDGFRA (<italic>P </italic>&#x0003c; 0.001, <italic>r </italic>= 0.493) and MYC (<italic>P </italic>&#x0003c; 0.001, <italic>r </italic>= 0.230). However, there were no significant correlation between mRNA expression level of HIF-1&#x003b1; and VEGF (<italic>P </italic>&#x0003c; 0.183, <italic>r </italic>= 0.128). Of all the six parameters, COX-2, MMP7 and PDGFRA were the top three factors with the largest correlation coefficients to HIF-1&#x003b1; (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Correlations between HIF-1&#x003b1; mRNA and other molecular markers as well as prognostic significance.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">HIF-1&#x003b1;</th><th align="center">COX-2</th><th align="center">MMP7</th><th align="center">PDGFRA</th><th align="center">MMP9</th><th align="center">MYC</th><th align="center">VEGF</th></tr></thead><tbody><tr><td align="center">Correlation (<italic>P</italic>)</td><td align="center">0.000</td><td align="center">&#x0003c; 0.001</td><td align="center">&#x0003c; 0.001</td><td align="center">&#x0003c; 0.001</td><td align="center">&#x0003c; 0.001</td><td align="center">0.016</td><td align="center">0.183</td></tr><tr><td align="center">Coefficient (<italic>r</italic>)</td><td align="center">1.000</td><td align="center">0.708</td><td align="center">0.593</td><td align="center">0.493</td><td align="center">0.384</td><td align="center">0.230</td><td align="center">0.128</td></tr><tr><td align="center">OS (<italic>P</italic>)</td><td align="center">0.012</td><td align="center">0.004</td><td align="center">0.010</td><td align="center">0.010</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td></tr><tr><td align="center">DFS (<italic>P</italic>)</td><td align="center">0.004</td><td align="center">0.010</td><td align="center">NS</td><td align="center">0.038</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td></tr></tbody></table><table-wrap-foot><p>Detailed legends: The <italic>P </italic>values for correlation were determined by spearman's coefficience. The <italic>P </italic>values for OS and DFS were calculated using multivariate Cox proportional hazards analysis. All factors were presented in different multivariable analysis respectively and variables were adopted for their prognostic significance by univariate analysis. NS means not significant (<italic>P </italic>&#x0003e; 0.05).</p></table-wrap-foot></table-wrap></sec><sec><title>Prognosis</title><p>The OS and DFS rates were 80.0% and 67.6% at 1 year, and 51.4% and 43.7% at 5 years respectively, for the whole study population.</p><p>On univariate analysis, sex, hepatitis history, cirrhosis, ALT level showed no prognostic significance for OS and DFS. AFP, &#x003b3;-GT, tumor differentiation, size, vascular invasion and encapsulation were found to be significant predictors for OS. Age, AFP, &#x003b3;-GT, tumor size, number, vascular invasion and encapsulation were predictors for DFS (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Univariate analyses of factors associated with survival and recurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center">Variables</th><th align="left" colspan="2">OS</th><th align="left" colspan="2">DFS</th></tr><tr><th/><th colspan="4"><hr/></th></tr><tr><th/><th align="center">Hazard ratio(95%CI)</th><th align="center"><italic>P</italic></th><th align="center">Hazard ratio(95%CI)</th><th align="center"><italic>P</italic></th></tr></thead><tbody><tr><td align="center">Age (year)</td><td align="center">0.982 (0.958-1.006)</td><td align="center">0.142</td><td align="center">0.976 (0.953-0.999)</td><td align="center">0.043</td></tr><tr><td align="center">Sex (female vs. male)</td><td align="center">0.630 (0.250-1.588)</td><td align="center">0.298</td><td align="center">0.673 (0.288-1.574)</td><td align="center">0.361</td></tr><tr><td align="center">Hepatitis history (no vs. yes)</td><td align="center">1.384 (0.498-3.848)</td><td align="center">0.534</td><td align="center">0.874 (0.395-1.935)</td><td align="center">0.739</td></tr><tr><td align="center">Liver cirrhosis (no vs. yes)</td><td align="center">1.855 (0.746-4.657)</td><td align="center">0.190</td><td align="center">0.904 (0.455-1.797)</td><td align="center">0.773</td></tr><tr><td align="center">AFP(ng/ml) (&#x02264; 20 vs. &#x0003e;20)</td><td align="center">2.183 (1.175-4.035)</td><td align="center">0.013</td><td align="center">2.553 (1.401-4.651)</td><td align="center">0.002</td></tr><tr><td align="center">ALT(U/L) (&#x02264; 40 vs. &#x0003e;40)</td><td align="center">0.877 (0.502-1.533)</td><td align="center">0.645</td><td align="center">0.817 (0.476-1.401)</td><td align="center">0.463</td></tr><tr><td align="center">&#x003b3;-GT(U/L) (&#x02264; 54 vs. &#x0003e;54)</td><td align="center">2.475 (1.313-4.664)</td><td align="center">0.005</td><td align="center">1.555 (0.888-2.722)</td><td align="center">0.123</td></tr><tr><td align="center">Tumor differentiation (I+II vs. III+IV)</td><td align="center">1.860 (1.062-3.297)</td><td align="center">0.030</td><td align="center">1.180 (0.691-2.014)</td><td align="center">0.545</td></tr><tr><td align="center">Tumor size (cm)</td><td align="center">1.179 (1.109-1.253)</td><td align="center">0.001</td><td align="center">1.152 (1.083-1.226)</td><td align="center">0.001</td></tr><tr><td align="center">Tumor number (single vs. multiple)</td><td align="center">1.597 (0.860-2.966)</td><td align="center">0.138</td><td align="center">2.851 (1.611-5.046)</td><td align="center">0.001</td></tr><tr><td align="center">Vascular invasion (no vs. yes)</td><td align="center">5.706 (2.971-10.960)</td><td align="center">0.001</td><td align="center">4.028 (2.288-7.089)</td><td align="center">0.001</td></tr><tr><td align="center">Encapsulation (complete vs. no)</td><td align="center">2.060 (1.135-3.737)</td><td align="center">0.017</td><td align="center">3.273 (1.773-6.044)</td><td align="center">0.001</td></tr><tr><td align="center">BCLC stage (A vs. B+C)</td><td align="center">6.225 (2.645-14.647)</td><td align="center">0.001</td><td align="center">2.601 (1.390-4.867)</td><td align="center">0.003</td></tr><tr><td align="center">COX-2 mRNA (low vs. high)</td><td align="center">2.042 (1.157-3.604)</td><td align="center">0.014</td><td align="center">1.839 (1.068-3.167)</td><td align="center">0.027</td></tr><tr><td align="center">MMP7 mRNA (low vs. high)</td><td align="center">2.278 (1.297-4.001)</td><td align="center">0.004</td><td align="center">0.753 (0.409-1.384)</td><td align="center">0.060</td></tr><tr><td align="center">MMP9 mRNA (low vs. high)</td><td align="center">0.740 (0.412-1.328)</td><td align="center">0.313</td><td align="center">1.711 (0.977-2.995)</td><td align="center">0.609</td></tr><tr><td align="center">VEGF mRNA (low vs. high)</td><td align="center">1.370 (0.756-2.483)</td><td align="center">0.299</td><td align="center">1.906 (1.096-3.126)</td><td align="center">0.022</td></tr><tr><td align="center">PDGFRA mRNA (low vs. high)</td><td align="center">1.801 (1.017-3.188)</td><td align="center">0.044</td><td align="center">1.771 (1.023-3.066)</td><td align="center">0.041</td></tr><tr><td align="center">MYC mRNA (low vs. high)</td><td align="center">0.948 (0.517-1.735)</td><td align="center">0.862</td><td align="center">0.867 (0.501-1.499)</td><td align="center">0.361</td></tr><tr><td align="center">HIF-1&#x003b1; mRNA (low vs. high)</td><td align="center">2.644 (1.524-4.655)</td><td align="center">0.001</td><td align="center">2.514 (1.462-4.324)</td><td align="center">0.001</td></tr><tr><td align="center">HIF-1&#x003b1; protein (low vs. high)</td><td align="center">1.874 (1.074-3.270)</td><td align="center">0.027</td><td align="center">2.004 (1.167-3.440)</td><td align="center">0.012</td></tr></tbody></table><table-wrap-foot><p>Detailed legends: The <italic>P </italic>values were calculated using univariate Cox proportional hazards analysis. Cut-point values of the experiment results were determined by the X-tile software.</p></table-wrap-foot></table-wrap><p>Univariate analysis revealed that the HIF-1&#x003b1; mRNA expression level was associated with both OS (P = 0.001) and DFS (P = 0.001) (Table <xref ref-type="table" rid="T4">4</xref>; Figure <xref ref-type="fig" rid="F1">1A</xref> and <xref ref-type="fig" rid="F1">1B</xref>). The OS rate for patients with high and low expression of HIF-1&#x003b1; mRNA were 63.2% and 88.9% at 1 year (P = 0.001), 30.4% and 62.5% at 5 year (<italic>P </italic>= 0.001) respectively. Similarly, the DFS rate for patients with high and low expression were 53.9% and 74.3% at 1 year (<italic>P </italic>= 0.004), 20.4% and 54.8% at 5 year (<italic>P </italic>= 0.004) respectively.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Kaplan-Meier analysis of overall and disease-free survival for HIF-1&#x003b1; mRNA and protein</bold>. Low expression of HIF-1&#x003b1; mRNA (A, B) or protein (C, D) was associated with both prolonged survival and reduced recurrence. The P values were determined by the log-rank test.</p></caption><graphic xlink:href="1471-2407-9-418-1"/></fig><p>Further, multivariate analysis confirmed that HIF-1&#x003b1; mRNA expression was independent prognostic factor for OS (<italic>P </italic>= 0.012, hazard ratio: 2.167, 95%CI: 1.185-3.965) and DFS (<italic>P </italic>= 0.004, hazard ratio: 2.359, 95%CI: 1.325-4.201). In addition, for DFS, the <italic>P </italic>value was the smallest and the hazard ratio was the largest among these factors (Table <xref ref-type="table" rid="T5">5</xref> and Additional files <xref ref-type="supplementary-material" rid="S3">3</xref>, <xref ref-type="supplementary-material" rid="S4">4</xref>, <xref ref-type="supplementary-material" rid="S5">5</xref>, <xref ref-type="supplementary-material" rid="S6">6</xref>, <xref ref-type="supplementary-material" rid="S7">7</xref> and <xref ref-type="supplementary-material" rid="S8">8</xref> ).</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Multivariate analyses of factors associated with survival and recurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Hazard ratio (95%CI)</th><th align="center"><italic>P</italic></th></tr></thead><tbody><tr><td align="center">OS</td><td/><td/></tr><tr><td align="center">AFP(ng/ml) (&#x02264; 20 vs. &#x0003e;20)</td><td align="center">1.320 (0.666-2.615)</td><td align="center">0.426</td></tr><tr><td align="center">&#x003b3;-GT(U/I) (&#x02264; 54 vs. &#x0003e;54)</td><td align="center">2.098 (1.073-4.103)</td><td align="center">0.030</td></tr><tr><td align="center">Tumor differentiation (I+II vs. III+IV)</td><td align="center">1.228 (0.661-2.279)</td><td align="center">0.516</td></tr><tr><td align="center">Tumor size (cm)</td><td align="center">1.102 (1.016-1.196)</td><td align="center">0.020</td></tr><tr><td align="center">Vascular invasion (no vs. yes)</td><td align="center">4.351 (1.992-9.500)</td><td align="center">0.001</td></tr><tr><td align="center">Capsule (complete vs. no)</td><td align="center">0.676 (0.332-1.375)</td><td align="center">0.280</td></tr><tr><td align="center">HIF-1&#x003b1; mRNA (low vs. high)</td><td align="center">2.167 (1.185-3.965)</td><td align="center">0.012</td></tr><tr><td align="center">COX-2 mRNA (low vs. high)</td><td align="center">2.557 (1.355-4.824)</td><td align="center">0.004</td></tr><tr><td align="center">MMP7 mRNA (low vs. high)</td><td align="center">2.287 (1.217-4.301)</td><td align="center">0.010</td></tr><tr><td align="center">PDGFRA mRNA (low vs. high)</td><td align="center">2.320 (1.225-4.394)</td><td align="center">0.010</td></tr><tr><td align="center">HIF-1&#x003b1; protein (low vs. high)</td><td align="center">2.108 (1.120-3.969)</td><td align="center">0.021</td></tr><tr><td align="center">DFS</td><td/><td/></tr><tr><td align="center">Age (year)</td><td align="center">0.990 (0.963-1.018)</td><td align="center">0.475</td></tr><tr><td align="center">AFP(ng/ml) (&#x02264; 20 vs. &#x0003e;20)</td><td align="center">1.707 (0.903-3.227)</td><td align="center">0.100</td></tr><tr><td align="center">Tumor size (cm)</td><td align="center">1.090 (0.997-1.191)</td><td align="center">0.060</td></tr><tr><td align="center">Tumor number (single vs. multiple)</td><td align="center">3.324 (1.818-6.079)</td><td align="center">0.001</td></tr><tr><td align="center">Vascular invasion (no vs. yes)</td><td align="center">2.453 (1.192-5.047)</td><td align="center">0.015</td></tr><tr><td align="center">Encapsulation (complete vs. no)</td><td align="center">1.573 (0.781-3.168)</td><td align="center">0.204</td></tr><tr><td align="center">HIF-1&#x003b1; mRNA (low vs. high)</td><td align="center">2.359 (1.325-4.201)</td><td align="center">0.004</td></tr><tr><td align="center">COX-2 mRNA (low vs. high)</td><td align="center">2.170 (1.201-3.921)</td><td align="center">0.010</td></tr><tr><td align="center">MMP7 mRNA (low vs. high)</td><td align="center">1.499 (0.830-2.707)</td><td align="center">0.179</td></tr><tr><td align="center">VEGF mRNA (low vs. high)</td><td align="center">1.702 (0.936-3.094)</td><td align="center">0.081</td></tr><tr><td align="center">PDGFRA mRNA (low vs. high)</td><td align="center">1.910 (1.038-3.514)</td><td align="center">0.038</td></tr><tr><td align="center">HIF-1&#x003b1; protein (low vs. high)</td><td align="center">2.265 (1.251-4.009)</td><td align="center">0.007</td></tr></tbody></table><table-wrap-foot><p>Detailed legends: The <italic>P </italic>values were calculated using multivariate Cox proportional hazards analysis. Variables were adopted for their prognostic significance by univariate analysis and no significant correlation between each other. COX-2 mRNA, PDGFRA mRNA, MMP7 mRNA, VEGF mRNA and HIF-1&#x003b1; protein were presented in different multivariable analysis respectively. (For details see Additional files <xref ref-type="supplementary-material" rid="S3">3</xref>, <xref ref-type="supplementary-material" rid="S4">4</xref>, <xref ref-type="supplementary-material" rid="S5">5</xref>, <xref ref-type="supplementary-material" rid="S6">6</xref>, <xref ref-type="supplementary-material" rid="S7">7</xref> and <xref ref-type="supplementary-material" rid="S8">8</xref>)</p></table-wrap-foot></table-wrap><p>Also, as for mRNA expression, COX-2 and PDGFRA, being correlated with HIF-1&#x003b1; with larger coefficients among the six parameters, showed significance for both OS and DFS on univariate analysis (COX-2: <italic>P </italic>= 0.014 for OS, <italic>P </italic>= 0.027 for DFS; PDGFRA: <italic>P </italic>= 0.044 for OS, <italic>P </italic>= 0.041 for DFS) and then strengthened on multivariate analysis (COX-2: <italic>P </italic>= 0.004 for OS, <italic>P </italic>= 0.010 for DFS; PDGFRA: <italic>P </italic>= 0.010 for OS, <italic>P </italic>= 0.038 for DFS). MMP7, which also correlated with HIF-1&#x003b1;, showed significance for OS on both uni- and multi-variate analyses, and patients with high MMP7 had a propensity of increased recurrence (<italic>P </italic>= 0.060). However, VEGF was only significant for DFS (<italic>P </italic>= 0.022) but has no influence on OS (<italic>P </italic>= 0.299) in univariate analysis. On multivariate analysis, VEGF was not a significant prognostic factor for recurrence (<italic>P </italic>= 0.081) any more. Neither MMP9 (<italic>P </italic>= 0.313 for OS, <italic>P </italic>= 0.607 for DFS) nor MYC (<italic>P </italic>= 0.862 for OS, <italic>P </italic>= 0.361 for DFS) had any prognostic value for either OS or DFS in HCC. (Tables <xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>)</p></sec><sec><title>Immunohistochemical confirmation</title><p>In HCC, positive staining of HIF-1&#x003b1; protein was observed mainly in cancer cells, and occasionally in infiltrating lymphocytes as well. In contrast, the fibroblasts and endothelial cells in tumor tissue always showed negative staining. HIF-1&#x003b1; protein was commonly detected in cytoplasm, whereas in some cases HIF-1&#x003b1; protein was detected mostly in nucleus. Representative images were showed in Figure <xref ref-type="fig" rid="F2">2</xref>.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Representative images of immunohistochemical staining</bold>. A: Negative expression of HIF-1&#x003b1; protein (&#x000d7; 200). B: Positive expression of HIF-1&#x003b1; protein (&#x000d7; 200). C: HIF-1&#x003b1; protein localized in the cytoplasm (&#x000d7; 400). D: HIF-1&#x003b1; protein localized in the nucleus (arrows) (&#x000d7; 400). E: Negative staining in fibroblasts and endothelial cells (arrows) (&#x000d7; 400). F: Positive staining in lymphocytes (arrows) (&#x000d7; 400).</p></caption><graphic xlink:href="1471-2407-9-418-2"/></fig><p>According to the optimal cut-point determined by the X-tile software, there were 71 (64.5%) patients with low expression and 39 (35.5%) patients with high expression. Although the immunohistochemical results were not totally in parallel with the RT-PCR results, protein expression of HIF-1&#x003b1; were highly correlated with the mRNA expression (<italic>P </italic>= 0.001). (See Additional file <xref ref-type="supplementary-material" rid="S9">9</xref>: Table S2 for correlations between HIF-1&#x003b1; mRNA and protein)</p><p>The tumor HIF-1&#x003b1; protein expression level has no association with patient age, tumor size, number, encapsulation, hepatitis history and preoperative AFP. Similar to HIF-1&#x003b1; mRNA, the tumor HIF-1&#x003b1; protein expression level was significantly associated with tumor vascular invasion (<italic>P </italic>= 0.027) and BCLC stages (<italic>P </italic>= 0.039). (Table <xref ref-type="table" rid="T2">2</xref>)</p><p>High expression of protein also means the poor outcome. Both OS and DFS were better in low expression group than that of high expression group. The OS rates for patient with high and low expression of HIF-1&#x003b1; protein were 69.2% and 85.9% at 1 year (<italic>P </italic>= 0.015), 39.8% and 58.0% at 5 years (<italic>P </italic>= 0.015) respectively. Also, the DFS rates for high and low expression were 50.8% and 76.5% at 1 year (<italic>P </italic>= 0.009), 30.3% and 51.2% at 5 year (<italic>P </italic>= 0.009) respectively.</p><p>On univariate analysis, tumor HIF-1&#x003b1; protein expression level was significant for both OS (<italic>P </italic>= 0.027) and DFS (<italic>P </italic>= 0.012) (Table <xref ref-type="table" rid="T4">4</xref>; Figure <xref ref-type="fig" rid="F1">1C</xref> and <xref ref-type="fig" rid="F1">1D</xref>), which were further authenticated on multivariate analysis (<italic>P </italic>= 0.021 for OS; <italic>P </italic>= 0.007 for DFS) (Table <xref ref-type="table" rid="T5">5</xref>). These may indicate that the prognostic value of HIF-1&#x003b1; was further validated on protein level.</p></sec></sec><sec><title>Discussion</title><p>It has been established that human solid tumors develop a pathophysiologic microenvironment during growth, characterized by an irregular microvascular network and regions of hypoxia [<xref ref-type="bibr" rid="B7">7</xref>]. Of clinical importance, hypoxia-related genes and proteins are potentially alternative endogenous markers, as compared with the inability and the cost of exogenous hypoxia markers [<xref ref-type="bibr" rid="B2">2</xref>]. In this study, we demonstrated for the first time that HIF-1&#x003b1;, at both mRNA and protein levels, is an independent prognostic factor for both survival and recurrence in HCC with the smallest <italic>P </italic>value as well as the largest hazard ratio for recurrence. In addition, we found that high expression of HIF-1&#x003b1; was significantly associated with an advanced stage and aggressive phenotypes. Several in vitro experimental studies sustained our results. In rat HCC models, tumor progression after hypoxia and chemotherapy was related to up-regulation of HIF-1&#x003b1; and subsequent VEGF production, and transcriptional blockade of HIF-1&#x003b1; could enhance their therapeutic efficacy [<xref ref-type="bibr" rid="B27">27</xref>]. In cell lines, HCC cell proliferation was inhibited by HIF-1&#x003b1; antisense oligonuclecotide [<xref ref-type="bibr" rid="B28">28</xref>]. As a key player in tumor progression, HIF-1&#x003b1; overexpression is associated with an increased mortality and treatment failure in various cancers although conflicting data exist [<xref ref-type="bibr" rid="B7">7</xref>]. The current study emphasizes the clinical significance of HIF-1&#x003b1;, suggesting that related therapy in the future is promising in reducing recurrence and prolonging survival [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>The underlying mechanisms that HIF-1&#x003b1; affects metastatic spread and selecting cells with more aggressive phenotypes have not been fully defined, but recent studies have shown a role for increased invasive capacity and inflammation [<xref ref-type="bibr" rid="B11">11</xref>]. Consistently, we found the importance of HIF-1&#x003b1; in HCC is associated with or may contribute to other markers related to inflammation, angiogenesis and invasion. COX-2, MMP7 and MMP9 were well-recognized factors in inflammation conditions [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. Among these molecules, COX-2, being involved in the chronic inflammation-related development of HCC, correlated with HIF-1&#x003b1; with the largest correlation coefficient (<italic>r </italic>= 0.708). Mechanistically, hypoxia potently triggers COX-2 transcription in many kinds of cells in primary culture [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Also, hypoxia influences the expression of MMPs although the mechanisms are controversial [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. The mRNA expression of MMP7, which can degrade various ECM proteins and support the role in tumor invasion and spread in HCC, has significant correlation to HIF-1&#x003b1; mRNA expression in our study (<italic>r </italic>= 0.593). However, MMP9, without any prognostic signifcance, seems to have less significant correlation to HIF-1&#x003b1; mRNA than MMP7 in HCC (<italic>r </italic>= 0.383). VEGF and PDGFRA promote the tumor angiogenesis in inflammation and hypoxia conditions [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. HIF-1&#x003b1; was often considered a master regulator of VEGF expression and angiogenesis in hypoxia. However, in our study, VEGF has no significant correlations with HIF-1&#x003b1;. As suggested, the regulation of VEGF expression may be come true by HIF-1&#x003b1;-independent pathways in hypoxia [<xref ref-type="bibr" rid="B34">34</xref>]. Otherwise, studies have revealed hypoxia can upregulate the expression of PDGFA [<xref ref-type="bibr" rid="B10">10</xref>], PDGFB [<xref ref-type="bibr" rid="B35">35</xref>] and PDGFRB [<xref ref-type="bibr" rid="B36">36</xref>], with little information on the correlation between HIF-1&#x003b1; and PDGFRA. Our study provide the preliminary data that HIF-1&#x003b1; positively correlated with and thus may upregulate PDGFRA, also a crucial angiogenic factor, in HCC (<italic>P </italic>&#x0003c; 0.001, <italic>r </italic>= 0.493).</p><p>All of these factors were conceived to promote tumor progression. Some of these molecules, such as COX-2, PDGFRA and MMP7, were believed to be prognostic factors in HCC according to our research. COX-2 may regulate HCC growth by COX-2-derived PG signaling pathway [<xref ref-type="bibr" rid="B37">37</xref>]. PDGFRA may regulate tumor angiogenesis by PDGFRA-p70S6K pathway which is related to the function of fibroblast growth factor (FGF) and expression of VEGF and hepatocytes growth factor (HGF) [<xref ref-type="bibr" rid="B18">18</xref>]. MMPs increase HCC invasion and growth through the degradation of extracellar matrix [<xref ref-type="bibr" rid="B38">38</xref>].</p><p>However, we propose that HIF-1&#x003b1;, with the smallest <italic>P </italic>value as well as the largest hazard ratio for DFS among these factors, may be the central factor to affect HCC outcome. Extensive researches have confirmed that HIF-1&#x003b1; controls many hundreds of target genes which play important roles in the cellular adaptation to hypoxia, and the proteins of these genes are involved in processes which can make cancer cells much more aggressive, such as angiogenesis, proliferation, apoptosis, energy metabolism and glucose transportation [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>In addition, the oncogene MYC also plays a crucial role in hypoxic response, and cooperates with HIF-1&#x003b1; to alter cellular metabolism and promote cancer progression [<xref ref-type="bibr" rid="B19">19</xref>]. In our study, MYC was positive correlated with HIF-1&#x003b1; (<italic>P </italic>= 0.016). However, the correlation coefficient was small (<italic>r </italic>= 0.230), and MYC has no prognostic value in HCC. The findings that MYC expression was repressed in the human hepatoma cell lines under extremely low oxygen concentrations may partly responsible for this non-significance [<xref ref-type="bibr" rid="B39">39</xref>].</p><p>In summary, HIF-1&#x003b1; was an independent prognosticator for both survival and recurrence in HCC. Although the correlations between HIF-1&#x003b1; and markers of inflammation, angiogenesis and the cooperative MYC oncogene are not very clear, we can hypothesize that HIF-1&#x003b1; was the crucial factor in HCC progression on the basis of our findings. The therapy targeting HIF-1&#x003b1; and associated molecules may profoundly reduce recurrence and prolong survival.</p></sec><sec><title>Conclusion</title><p>HIF-1&#x003b1; was an independent prognosticator for both survival and recurrence in HCC. Markers of inflammation, angiogenesis and the cooperative MYC oncogene, who have closer correlation with HIF-1&#x003b1;, seem to be better for prognostic stratification, suggesting that HIF-1&#x003b1; was one of the most crucial factors in HCC progression. Attaching importance to HIF-1&#x003b1; and related molecules may improve the prognostic stratification and therapeutic technique.</p></sec><sec><title>Abbreviations</title><p>AFP: alpha-fetoprotein; BCLC stage: Barcelona Clinic Liver Cancer stage; CI: confidence interval; COX-2: cyclooxygenase-2; DFS: disease-free survival; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HIF-1&#x003b1;: hypoxia-inducible factor 1, alpha subunit; HPRT: hypoxanthine-guanine phosphoribosyltransferase; MMP: matrix metalloproteinase; OS: overall survival; PDGFRA: platelet-derived growth factor receptor, alpha polypeptide; RT-PCR: polymerase chain reaction; TBP: TATA binding protein; VEGF: vascular endothelial growth factor.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JF developed the study concept, aims and initiated the project. QG and CXD performed the experimental work described in the study and were both responsible for the drafting of the manuscript. SJQ supervised the process of the whole research. JZ and BHZ provided valuable scientific suggestions. MJJ, MYC and YFX have participated in its design and coordination. All authors have read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/418/prepub">http://www.biomedcentral.com/1471-2407/9/418/prepub</ext-link></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Figure S1: Relative expression of HIF-1&#x003b1;, COX-2, MMP7, MMP9, VEGF, PDGFRA and MYC with the cut-off value determined by the X-tile software</bold>. The blue dots show the relative value of mRNA expression. The red lines show the cut-off value.</p></caption><media xlink:href="1471-2407-9-418-S1.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Table S1: Degree of HIF-1&#x003b1; immunohistochemistry in tissue array of HCC</bold>. I, no staining; II, nuclear staining in less than 10% of cells and/or with weak cytoplasmic staining; III, nuclear staining in 10%-50% of cells and/or with moderate cytoplasmic staining; IV, nuclear staining in more than 50% of cells and/or with strong cytoplasmic staining.</p></caption><media xlink:href="1471-2407-9-418-S2.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p>Figure S2: Kaplan-Meier analysis of OS and DFS for COX-2, MMP7, MMP9, VEGF, PDGFRA and MYC mRNA</p></caption><media xlink:href="1471-2407-9-418-S3.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p>Table S3: Multivariate analyses of variables associated with survival and recurrence including mRNA expression of COX-2 as co-variable</p></caption><media xlink:href="1471-2407-9-418-S4.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title>Additional file 5</title><p>Table S4: Multivariate analyses of variables associated with survival and recurrence including mRNA expression of PDGFRA as co-variable</p></caption><media xlink:href="1471-2407-9-418-S5.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S6"><caption><title>Additional file 6</title><p>Table S5: Multivariate analyses of variables associated with survival and recurrence including mRNA expression of MMP7 as co-variable</p></caption><media xlink:href="1471-2407-9-418-S6.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S7"><caption><title>Additional file 7</title><p><bold>Table S6: Multivariate analyses of variables associated with survival and recurrence including protein expression of HIF-1&#x003b1; as co-variable</bold>. (P = 0.021 for OS, P = 0.007 for DFS).</p></caption><media xlink:href="1471-2407-9-418-S7.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S8"><caption><title>Additional file 8</title><p><bold>Table S7: Multivariate analyses of variables associated with survival and recurrence including mRNA expression of VEGF as co-variable</bold>. (P = 0.081 for DFS).</p></caption><media xlink:href="1471-2407-9-418-S8.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S9"><caption><title>Additional file 9</title><p>Table S2: Correlations between HIF-1&#x003b1; mRNA and protein expression.</p></caption><media xlink:href="1471-2407-9-418-S9.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>This study was funded by Key Project of the Chinese Ministry of Education (no. 107039), National Key Sci-Tech Special Project of China (no. 2008ZX10002-018, 2008ZX10002-019), National Natural Science Foundation of China (no. 30700794) and the Doctoral Fund of Ministry of Education of China (no. 20060246075).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Korangy</surname><given-names>F</given-names></name><article-title>Immunotherapy of HCC</article-title><source>Rev Recent Clin Trials</source><year>2008</year><volume>3</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.2174/157488708783330549</pub-id><pub-id pub-id-type="pmid">18474013</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Vengellur</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>JM</given-names></name><name><surname>Hogenesch</surname><given-names>JB</given-names></name><name><surname>LaPres</surname><given-names>JJ</given-names></name><article-title>Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells</article-title><source>Physiol Genomics</source><year>2005</year><volume>22</volume><issue>3</issue><fpage>308</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1152/physiolgenomics.00045.2004</pub-id><pub-id pub-id-type="pmid">15942021</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Gwak</surname><given-names>GY</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><article-title>Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression</article-title><source>J Hepatol</source><year>2005</year><volume>42</volume><issue>3</issue><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2004.11.020</pub-id><pub-id pub-id-type="pmid">15710218</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>KR</given-names></name><name><surname>Moon</surname><given-names>HE</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><article-title>Hypoxia-induced angiogenesis in human hepatocellular carcinoma</article-title><source>J Mol Med</source><year>2002</year><volume>80</volume><issue>11</issue><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1007/s00109-002-0380-0</pub-id><pub-id pub-id-type="pmid">12436347</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Miyoshi</surname><given-names>A</given-names></name><name><surname>Kitajima</surname><given-names>Y</given-names></name><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Ohtaka</surname><given-names>K</given-names></name><name><surname>Nagasawa</surname><given-names>H</given-names></name><name><surname>Uto</surname><given-names>Y</given-names></name><name><surname>Hori</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><article-title>Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner</article-title><source>Int J Oncol</source><year>2006</year><volume>29</volume><issue>6</issue><fpage>1533</fpage><lpage>1539</lpage><pub-id pub-id-type="pmid">17088993</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>XZ</given-names></name><name><surname>Xie</surname><given-names>GR</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><article-title>Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma</article-title><source>J Gastroenterol Hepatol</source><year>2007</year><volume>22</volume><issue>8</issue><fpage>1178</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2007.04997.x</pub-id><pub-id pub-id-type="pmid">17559361</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Bertout</surname><given-names>JA</given-names></name><name><surname>Patel</surname><given-names>SA</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name><article-title>The impact of O2 availability on human cancer</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><issue>12</issue><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1038/nrc2540</pub-id><pub-id pub-id-type="pmid">18987634</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Hirota</surname><given-names>K</given-names></name><article-title>Hypoxia-inducible factor 1, a master transcription factor of cellular hypoxic gene expression</article-title><source>J Anesth</source><year>2002</year><volume>16</volume><issue>2</issue><fpage>150</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1007/s005400200011</pub-id><pub-id pub-id-type="pmid">14517667</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Klatte</surname><given-names>T</given-names></name><name><surname>Seligson</surname><given-names>DB</given-names></name><name><surname>Riggs</surname><given-names>SB</given-names></name><name><surname>Leppert</surname><given-names>JT</given-names></name><name><surname>Berkman</surname><given-names>MK</given-names></name><name><surname>Kleid</surname><given-names>MD</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Kabbinavar</surname><given-names>FF</given-names></name><name><surname>Pantuck</surname><given-names>AJ</given-names></name><name><surname>Belldegrun</surname><given-names>AS</given-names></name><article-title>Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><issue>24</issue><fpage>7388</fpage><lpage>7393</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0411</pub-id><pub-id pub-id-type="pmid">18094421</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>AC</given-names></name><name><surname>Mori</surname><given-names>R</given-names></name><name><surname>Vallbohmer</surname><given-names>D</given-names></name><name><surname>Brabender</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name><name><surname>Drebber</surname><given-names>U</given-names></name><name><surname>Baldus</surname><given-names>SE</given-names></name><name><surname>Cooc</surname><given-names>J</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>R</given-names></name><article-title>High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF</article-title><source>Neoplasia</source><year>2008</year><volume>10</volume><issue>7</issue><fpage>674</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">18592007</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>CT</given-names></name><article-title>Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation</article-title><source>J Physiol</source><year>2008</year><volume>586</volume><issue>Pt 17</issue><fpage>4055</fpage><lpage>4059</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2008.157669</pub-id><pub-id pub-id-type="pmid">18599532</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Simon</surname><given-names>JM</given-names></name><article-title>Hypoxia and angiogenesis</article-title><source>Bull Cancer</source><year>2007</year><volume>94</volume><issue>Spec No</issue><fpage>S160</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">17846000</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Gordan</surname><given-names>JD</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name><article-title>HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation</article-title><source>Cancer Cell</source><year>2007</year><volume>12</volume><issue>2</issue><fpage>108</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.07.006</pub-id><pub-id pub-id-type="pmid">17692803</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Rajakariar</surname><given-names>R</given-names></name><name><surname>Yaqoob</surname><given-names>MM</given-names></name><name><surname>Gilroy</surname><given-names>DW</given-names></name><article-title>COX-2 in inflammation and resolution</article-title><source>Mol Interv</source><year>2006</year><volume>6</volume><issue>4</issue><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1124/mi.6.4.6</pub-id><pub-id pub-id-type="pmid">16960142</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Lichtinghagen</surname><given-names>R</given-names></name><name><surname>Michels</surname><given-names>D</given-names></name><name><surname>Haberkorn</surname><given-names>CI</given-names></name><name><surname>Arndt</surname><given-names>B</given-names></name><name><surname>Bahr</surname><given-names>M</given-names></name><name><surname>Flemming</surname><given-names>P</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Boeker</surname><given-names>KH</given-names></name><article-title>Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C</article-title><source>J Hepatol</source><year>2001</year><volume>34</volume><issue>2</issue><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(00)00037-4</pub-id><pub-id pub-id-type="pmid">11281552</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Reif</surname><given-names>S</given-names></name><name><surname>Somech</surname><given-names>R</given-names></name><name><surname>Brazovski</surname><given-names>E</given-names></name><name><surname>Reich</surname><given-names>R</given-names></name><name><surname>Belson</surname><given-names>A</given-names></name><name><surname>Konikoff</surname><given-names>FM</given-names></name><name><surname>Kessler</surname><given-names>A</given-names></name><article-title>Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C</article-title><source>Digestion</source><year>2005</year><volume>71</volume><issue>2</issue><fpage>124</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1159/000084626</pub-id><pub-id pub-id-type="pmid">15785038</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>JL</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><article-title>Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications</article-title><source>Front Biosci</source><year>2009</year><volume>14</volume><fpage>3094</fpage><lpage>3110</lpage><pub-id pub-id-type="doi">10.2741/3438</pub-id><pub-id pub-id-type="pmid">19273260</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Tsutsumi</surname><given-names>N</given-names></name><name><surname>Yonemitsu</surname><given-names>Y</given-names></name><name><surname>Shikada</surname><given-names>Y</given-names></name><name><surname>Onimaru</surname><given-names>M</given-names></name><name><surname>Tanii</surname><given-names>M</given-names></name><name><surname>Okano</surname><given-names>S</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Hashizume</surname><given-names>M</given-names></name><name><surname>Maehara</surname><given-names>Y</given-names></name><article-title>Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis</article-title><source>Circ Res</source><year>2004</year><volume>94</volume><issue>9</issue><fpage>1186</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000126925.66005.39</pub-id><pub-id pub-id-type="pmid">15059936</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Dang</surname><given-names>CV</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Yustein</surname><given-names>J</given-names></name><article-title>The interplay between MYC and HIF in cancer</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><issue>1</issue><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nrc2274</pub-id><pub-id pub-id-type="pmid">18046334</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>SJ</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Xiao</surname><given-names>YS</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>YW</given-names></name><name><surname>Tang</surname><given-names>ZY</given-names></name><article-title>Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>18</issue><fpage>2586</fpage><lpage>2593</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.4565</pub-id><pub-id pub-id-type="pmid">17577038</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bru</surname><given-names>C</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name><article-title>Prognosis of hepatocellular carcinoma: the BCLC staging classification</article-title><source>Semin Liver Dis</source><year>1999</year><volume>19</volume><issue>3</issue><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1007122</pub-id><pub-id pub-id-type="pmid">10518312</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>SJ</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>YH</given-names></name><name><surname>Xiao</surname><given-names>YS</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>XW</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><article-title>Selection of reference genes for real-time PCR in human hepatocellular carcinoma tissues</article-title><source>J Cancer Res Clin Oncol</source><year>2008</year><volume>134</volume><issue>9</issue><fpage>979</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1007/s00432-008-0369-3</pub-id><pub-id pub-id-type="pmid">18317805</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Qiu</surname><given-names>SJ</given-names></name><name><surname>Yamato</surname><given-names>I</given-names></name><name><surname>Sho</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>BZ</given-names></name><name><surname>Shi</surname><given-names>YH</given-names></name><name><surname>Xiao</surname><given-names>YS</given-names></name><article-title>Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><issue>3</issue><fpage>971</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1608</pub-id><pub-id pub-id-type="pmid">19188168</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Laughner</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>M</given-names></name><name><surname>Hilton</surname><given-names>DA</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name><name><surname>Buechler</surname><given-names>P</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Simons</surname><given-names>JW</given-names></name><article-title>Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><issue>22</issue><fpage>5830</fpage><lpage>5835</lpage><pub-id pub-id-type="pmid">10582706</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><article-title>The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein</article-title><source>Dig Dis Sci</source><year>2008</year><volume>53</volume><issue>12</issue><fpage>3225</fpage><lpage>3233</lpage><pub-id pub-id-type="doi">10.1007/s10620-008-0296-9</pub-id><pub-id pub-id-type="pmid">18465238</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Camp</surname><given-names>RL</given-names></name><name><surname>Dolled-Filhart</surname><given-names>M</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name><article-title>X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><issue>21</issue><fpage>7252</fpage><lpage>7259</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0713</pub-id><pub-id pub-id-type="pmid">15534099</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>ZF</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>To</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>DW</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name><article-title>The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>15</issue><fpage>5496</fpage><lpage>5503</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3311</pub-id><pub-id pub-id-type="pmid">15289360</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Qiao</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Krissansen</surname><given-names>GW</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><article-title>Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma</article-title><source>Cancer Sci</source><year>2008</year><volume>99</volume><issue>10</issue><fpage>2055</fpage><lpage>2061</lpage><pub-id pub-id-type="pmid">19016766</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Acker</surname><given-names>T</given-names></name><name><surname>Plate</surname><given-names>KH</given-names></name><article-title>Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology</article-title><source>Cancer Treat Res</source><year>2004</year><volume>117</volume><fpage>219</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">15015563</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Schmedtje</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Ji</surname><given-names>YS</given-names></name><name><surname>Liu</surname><given-names>WL</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name><name><surname>Runge</surname><given-names>MS</given-names></name><article-title>Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><issue>1</issue><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.1.601</pub-id><pub-id pub-id-type="pmid">8995303</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Hierholzer</surname><given-names>C</given-names></name><name><surname>Harbrecht</surname><given-names>BG</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Tweardy</surname><given-names>DJ</given-names></name><article-title>Hypoxia-inducible factor-1 activation and cyclo-oxygenase-2 induction are early reperfusion-independent inflammatory events in hemorrhagic shock</article-title><source>Arch Orthop Trauma Surg</source><year>2001</year><volume>121</volume><issue>4</issue><fpage>219</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1007/s004020000211</pub-id><pub-id pub-id-type="pmid">11317684</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Osinsky</surname><given-names>SP</given-names></name><name><surname>Ganusevich</surname><given-names>II</given-names></name><name><surname>Bubnovskaya</surname><given-names>LN</given-names></name><name><surname>Valkovskaya</surname><given-names>NV</given-names></name><name><surname>Kovelskaya</surname><given-names>AV</given-names></name><name><surname>Sergienko</surname><given-names>TK</given-names></name><name><surname>Zimina</surname><given-names>SV</given-names></name><article-title>Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis</article-title><source>Exp Oncol</source><year>2005</year><volume>27</volume><issue>3</issue><fpage>202</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">16244581</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Scaldaferri</surname><given-names>F</given-names></name><name><surname>Vetrano</surname><given-names>S</given-names></name><name><surname>Sans</surname><given-names>M</given-names></name><name><surname>Arena</surname><given-names>V</given-names></name><name><surname>Straface</surname><given-names>G</given-names></name><name><surname>Stigliano</surname><given-names>E</given-names></name><name><surname>Repici</surname><given-names>A</given-names></name><name><surname>Sturm</surname><given-names>A</given-names></name><name><surname>Malesci</surname><given-names>A</given-names></name><name><surname>Panes</surname><given-names>J</given-names></name><article-title>VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><issue>2</issue><fpage>585</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.09.064</pub-id><pub-id pub-id-type="pmid">19013462</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Arany</surname><given-names>Z</given-names></name><name><surname>Foo</surname><given-names>SY</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Ruas</surname><given-names>JL</given-names></name><name><surname>Bommi-Reddy</surname><given-names>A</given-names></name><name><surname>Girnun</surname><given-names>G</given-names></name><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Laznik</surname><given-names>D</given-names></name><name><surname>Chinsomboon</surname><given-names>J</given-names></name><name><surname>Rangwala</surname><given-names>SM</given-names></name><article-title>HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha</article-title><source>Nature</source><year>2008</year><volume>451</volume><issue>7181</issue><fpage>1008</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/nature06613</pub-id><pub-id pub-id-type="pmid">18288196</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Eng</surname><given-names>E</given-names></name><name><surname>Holgren</surname><given-names>C</given-names></name><name><surname>Hubchak</surname><given-names>S</given-names></name><name><surname>Naaz</surname><given-names>P</given-names></name><name><surname>Schnaper</surname><given-names>HW</given-names></name><article-title>Hypoxia regulates PDGF-B interactions between glomerular capillary endothelial and mesangial cells</article-title><source>Kidney Int</source><year>2005</year><volume>68</volume><issue>2</issue><fpage>695</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00448.x</pub-id><pub-id pub-id-type="pmid">16014047</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>SX</given-names></name><name><surname>Gozal</surname><given-names>D</given-names></name><name><surname>Sachleben</surname><given-names>LR</given-names><suffix>Jr</suffix></name><name><surname>Rane</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>JB</given-names></name><name><surname>Gozal</surname><given-names>E</given-names></name><article-title>Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells</article-title><source>FASEB J</source><year>2003</year><volume>17</volume><issue>12</issue><fpage>1709</fpage><lpage>1711</lpage><pub-id pub-id-type="pmid">12958184</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>T</given-names></name><article-title>Cyclooxygenase-2 in hepatocellular carcinoma</article-title><source>Cancer Treat Rev</source><year>2006</year><volume>32</volume><issue>1</issue><fpage>28</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2005.10.004</pub-id><pub-id pub-id-type="pmid">16337744</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Matsunaga</surname><given-names>Y</given-names></name><name><surname>Koda</surname><given-names>M</given-names></name><name><surname>Murawaki</surname><given-names>Y</given-names></name><article-title>Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue</article-title><source>Res Commun Mol Pathol Pharmacol</source><year>2004</year><volume>115-116</volume><fpage>143</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">17564313</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Mazure</surname><given-names>NM</given-names></name><name><surname>Chauvet</surname><given-names>C</given-names></name><name><surname>Bois-Joyeux</surname><given-names>B</given-names></name><name><surname>Bernard</surname><given-names>MA</given-names></name><name><surname>Nacer-Cherif</surname><given-names>H</given-names></name><name><surname>Danan</surname><given-names>JL</given-names></name><article-title>Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><issue>4</issue><fpage>1158</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">11861398</pub-id></mixed-citation></ref></ref-list></back></article>